PT - JOURNAL ARTICLE AU - Martin Wiegand AU - Sarah L. Cowan AU - Claire S. Waddington AU - David J. Halsall AU - Victoria L. Keevil AU - Brian D. M. Tom AU - Vince Taylor AU - Effrossyni Gkrania-Klotsas AU - Jacobus Preller AU - Robert J. B. Goudie TI - Development and validation of a dynamic 48-hour in-hospital prognostic risk stratification for COVID-19 in a UK teaching hospital: a retrospective cohort study AID - 10.1101/2021.02.15.21251150 DP - 2021 Jan 01 TA - medRxiv PG - 2021.02.15.21251150 4099 - http://medrxiv.org/content/early/2021/02/18/2021.02.15.21251150.short 4100 - http://medrxiv.org/content/early/2021/02/18/2021.02.15.21251150.full AB - We propose a prognostic dynamic risk stratification for 48-hour in-hospital mortality in patients with COVID-19, using demographics and routinely-collected observations and laboratory tests: age, Clinical Frailty Scale score, heart rate, respiratory rate, SpO2/FiO2 ratio, white cell count, acidosis (pH < 7.35) and Interleukin-6. We train and validate the model using data from a UK teaching hospital, adopting a landmarking approach that accounts for competing risks and informative missingness. Internal validation of the model on the first wave of patients presenting between March 1 and September 12, 2020 achieves an AUROC of 0.90 (95% CI 0.87–0.93). Temporal validation on patients presenting between September 13, 2020 and January 1, 2021 gives an AUROC of 0.91 (95% CI 0.88-0.95). The resulting mortality stratification tool has the potential to provide physicians with an assessment of a patient’s evolving prognosis throughout the course of active hospital treatment.Competing Interest StatementThe authors have declared no competing interest.Funding StatementMartin Wiegand was funded by the NIHR Cambridge Biomedical Research Centre [BRC-1215-20014]. Victoria L. Keevil was funded by the MRC/NIHR Clinical Academic Research Partnership Grant (CARP) [grant code MR/T023902/1]. Vince Taylor was funded by the Cancer Research UK Cambridge Centre. Effrossyni Gkrania-Klotsas was supported by the NIHR Clinical Research Network (CRN) Greenshoots Award. Brian D. M. Tom and Robert J. B. Goudie were funded by the UKRI Medical Research Council (MRC) [programme code MC_UU_00002/2] and supported by the NIHR Cambridge Biomedical Research Centre [BRC-1215-20014]. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by a UK Health Research Authority ethics committee (20/WM/0125). Patient consent was waived because the de-identified data presented here were collected during routine clinical practice; there was no requirement for informed consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe de-identified data that support the findings of this study are available from Cambridge University Hospitals but restrictions apply to the availability of these data, which were used under license for the current study, and so are not publicly available. Data are however available from the authors upon reasonable request with permission of Cambridge University Hospitals.